News
RSS feedUS Pilot Trial of Psilocybin-Assisted Therapy for Veterans' PTSD Reports Early Results
Ohio State University researchers have published results from a 12-person open-label pilot trial of psilocybin-assisted therapy in veterans with severe treatment-resistant PTSD.
US Doctor Charged With Manslaughter Over Death at Unregulated MDMA–Ketamine Retreat
A Florida case involving a fatal 'Heart Protocol' ceremony is a stark reminder of why vetting matters before attending any psychedelic retreat, at home or abroad.
Eli Lilly to Acquire Psychedelic Developer AtaiBeckley in Deal Worth up to US$3.8 Billion
The world's largest pharmaceutical company has agreed to buy AtaiBeckley, developer of an intranasal 5-MeO-DMT candidate for treatment-resistant depression.
US FDA Finalises Psychedelic Trial Guidance and Sets September Public Hearing
The US drug regulator has finalised its guidance for psychedelic clinical trials and will hold a public hearing on supervised therapeutic use in September 2026.
TGA Relaxes In-Room Requirements for Authorised Prescriber Sessions
A 2026 regulatory update changes who must be physically present during MDMA/psilocybin dosing sessions under Australia's Authorised Prescriber scheme.
Synthesis Institute Resumes Bookings After 2023 Financial Collapse
The Netherlands-based psilocybin retreat operator, which underwent a well-documented 2023 collapse, has 2026 retreat dates live on its booking system.
Oregon's HB 2387 Expands Facilitator Protections From 1 January 2026
A new Oregon law allows licensed healthcare providers who are also psilocybin facilitators to deliver services without professional-board discipline risk.
Clarion Clinics Rebrands as Mind Medicine Australia Clinic
Melbourne's Clarion Clinics, one of Australia's first dedicated psychedelic-assisted therapy clinics, now operates under a new name.